Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial.

被引：0
|
作者：
Polikoff, J
Mitchell, EP
Badarinath, S
Graham, CD
Jennis, A
Chen, TT
Gustafson, TN
Langer, C
机构：
[1] Kaiser Permanente, San Diego, CA USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Florida Oncol Assoc, Jacksonville, FL USA
[4] Charleston Canc Ctr, Charleston, SC USA
[5] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：264S / 264S
页数：1
相关论文
共 50 条
  • [31] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
    Beslija, S.
    Koza, I.
    Ocvirk, J.
    Ciuleanu, T.
    Kurteva, G.
    Papamichael, D.
    Vrbanec, D.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
  • [32] Neutrophil/lymphocyte ratio as surrogate of cetuximab antibody-dependent cell-mediated cytotoxicity in first line metastatic colorectal cancer: A preliminary and exploratory analysis of the ERMES phase III trial.
    Calegari, Maria Alessandra
    Orlandi, Armando
    Basso, Michele
    Di Dio, Carmela
    Bensi, Maria
    Ramundo, Matteo
    Maiello, Evaristo
    Cassata, Antonino
    Tamburini, Emiliano
    Di Costanzo, Francesco
    Normanno, Nicola
    Pinto, Carmine
    Barone, Carlo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Wang, Chen
    Hao, Chunfang
    Wang, Xiaorui
    Meng, Wenjin
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial
    Wang, De-Shen
    Ren, Chao
    Li, Shan-Shan
    Fong, William Pat
    Wu, Xiao-Jun
    Xiao, Jian
    Li, Bin-Kui
    Zheng, Yun
    Ding, Pei-Rong
    Chen, Gong
    Qiu, Miao-Zhen
    Wang, Zhi-Qiang
    Wang, Feng-Hua
    Luo, Hui-Yan
    Wang, Feng
    Wang, Xiao-Zhong
    Wang, Ling-Yun
    Xie, De-Jin
    Chen, Tao
    Li, Li-Ren
    Lu, Zhen-Hai
    Zhai, Xiao-Hui
    Liu, Tian-Shu
    Yuan, Ying
    Chen, Jia-Qi
    Tan, Qiong
    Pan, Zhi-Zhong
    Wan, De-Sen
    Zhang, Rong
    Yuan, Yun-Fei
    Xu, Rui-Hua
    Li, Yu-Hong
    PLOS MEDICINE, 2024, 21 (05)
  • [35] FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
    Lin, Rongbo
    Li, Hui
    Chen, Yigui
    Zhu, Jinfeng
    Lin, Peicheng
    Chen, Wujin
    Fang, Wenzheng
    Liu, Jie
    Zhao, Shen
    Fan, Nanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [36] TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC):: Preliminary results of a multicenter randomized phase II trial.
    Grávalos, C
    García-Girón, C
    León, AI
    Salud, A
    Esteban, B
    Sevilla, I
    Maurel, J
    Murias, A
    García-Rico, E
    Cortés-Funes, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 269S - 269S
  • [37] Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.
    Jankowski, Janusz
    de Caestecker, John
    Love, Sharon
    Reilly, Gavin
    Ang, Yeng
    Ragunath, Krish
    Tucker, Arthur
    Penman, Ian
    Rodgers, Colin
    Roffe, Emma
    Brooks, Claire E.
    Attwood, Stephen
    Morris, Danielle
    Harrison, Rebecca
    Bhandari, Pradeep
    Watson, Peter
    Sanders, Scott
    Barr, Hugh
    Moayyedi, Paul
    Neale, James
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [38] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
    Schmoll, Hans-Joachim
    Garlipp, Benjamin
    Junghanss, Christian
    Leithaeuser, Malte
    Vogel, Arndt
    Schaefers, Michael
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Florschuetz, Axel
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Steighardt, Joerg
    Meinert, Fabian Maximilian
    Cygon, Franziska
    Stein, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
    Cascinu, Stefano
    Zaniboni, Alberto
    Lonardi, Sara
    Rosati, Gerardo
    Nasti, Guglielmo
    Giordano, Monica
    Corsi, Domenico C.
    Ferrau, Francesco
    Iaffaioli, Rosario Vincenz
    Marchetti, Paolo
    Aglietta, Massimo
    Bilancia, Domenico
    Ronzoni, Monica
    Floriani, Irene Claudia
    Labianca, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [40] Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction
    Elsoueidi, Raymond
    Craig, Jessica
    Mourad, Hesham
    Richa, Elie M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (02): : 155 - 160
12345